Dataset Information
Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer.
Ontology highlight
ABSTRACT: Background and aim
In Stage IIIA-N2 non-small cell lung cancer (NSCLC), the accuracy of combined positron-emission tomography/computed tomography imaging (PET-CT), together with mediastinal staging techniques, has led to a wide range of challenging clinical scenarios in terms of therapeutic management. Concurrent chemoradiotherapy followed by consolidation immunotherapy remains the standard of care. In patients with potentially-resectable disease, surgery plays an important role in multimodal therapy. The introduction of targeted therapies and immune-checkpoint inhibitors has revolutionized multimodal treatment. In the present article, we review current treatment options and future trends in stage IIIA-N2 NSCLC.Relevance for patients
This article provides insight into the current status of multimodal treatment for NSCLC to support decision-making in routine clinical practice.
SUBMITTER: Montemuino Muniz S
PROVIDER: S-EPMC8177852 | biostudies-literature | 2021 Apr
REPOSITORIES: biostudies-literature
Publications
Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer.
Journal of clinical and translational research 20210416 2
<h4>Background and aim</h4>In Stage IIIA-N2 non-small cell lung cancer (NSCLC), the accuracy of combined positron-emission tomography/computed tomography imaging (PET-CT), together with mediastinal staging techniques, has led to a wide range of challenging clinical scenarios in terms of therapeutic management. Concurrent chemoradiotherapy followed by consolidation immunotherapy remains the standard of care. In patients with potentially-resectable disease, surgery plays an important role in multi ...[more]